TY - JOUR A1 - Üçeyler, Nurcan A1 - Kewenig, Susanne A1 - Kittel-Schneider, Sarah A1 - Fallgatter, Andreas J. A1 - Sommer, Claudia T1 - Increased cortical activation upon painful stimulation in fibromyalgia syndrome JF - BMC Neurology N2 - Background Fibromyalgia syndrome (FMS) is a chronic condition characterized by widespread pain and associated symptoms. We investigated cerebral activation in FMS patients by functional near-infrared spectroscopy (fNIRS). Methods Two stimulation paradigms were applied: a) painful pressure stimulation at the dorsal forearm; b) verbal fluency test (VFT). We prospectively recruited 25 FMS patients, ten patients with unipolar major depression (MD) without pain, and 35 healthy controls. All patients underwent neurological examination and all subjects were investigated with questionnaires (pain, depression, FMS, empathy). Results FMS patients had lower pressure pain thresholds than patients with MD and controls (p < 0.001) and reported higher pain intensity (p < 0.001). Upon unilateral pressure pain stimulation fNIRS recordings revealed increased bilateral cortical activation in FMS patients compared to controls (p < 0.05). FMS patients also displayed a stronger contralateral activity over the dorsolateral prefrontal cortex in direct comparison to patients with MD (p < 0.05). While all three groups performed equally well in the VFT, a frontal deficit in cortical activation was only found in patients with depression (p < 0.05). Performance and cortical activation correlated negatively in FMS patients (p < 0.05) and positively in patients with MD (p < 0.05). Conclusion Our data give further evidence for altered central nervous processing in patients with FMS and the distinction between FMS and MD. KW - fibromyalgia syndrome KW - depression KW - cortical activation KW - pain KW - near-infrared spectroscopy Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-125230 VL - 15 IS - 210 ER - TY - JOUR A1 - Kittel-Schneider, Sarah A1 - Kenis, Gunter A1 - Schek, Julia A1 - van den Hove, Daniel A1 - Prickaerts, Jos A1 - Lesch, Klaus-Peter A1 - Steinbusch, Harry A1 - Reif, Andreas T1 - Expression of monoamine transporters, nitric oxide synthase 3, and neurotrophin genes in antidepressant-stimulated astrocytes JF - Frontiers in Psychiatry N2 - Background: There is increasing evidence that glial cells play a role in the pathomechanisms of mood disorders and the mode of action of antidepressant drugs. Methods: To examine whether there is a direct effect on the expression of different genes encoding proteins that have been implicated in the pathophysiology of affective disorders, primary astrocyte cell cultures from rats were treated with two different antidepressant drugs, imipramine and escitalopram, and the RNA expression of brain-derived neurotrophic factor (Bdnf), serotonin transporter (5Htt), dopamine transporter (Dat), and endothelial nitric oxide synthase (Nos3) was examined. Results: Stimulation of astroglial cell culture with imipramine, a tricyclic antidepressant, led to a significant increase of the Bdnf RNA level whereas treatment with escitalopram did not. In contrast, 5Htt was not differentially expressed after antidepressant treatment. Finally, neither Dat nor Nos3 RNA expression was detected in cultured astrocytes. Conclusion: These data provide further evidence for a role of astroglial cells in the molecular mechanisms of action of antidepressants. KW - monoamine transporters KW - BDNF KW - geneexpression KW - astrocytes KW - glia KW - depression KW - antidepressant KW - mechanismofaction KW - nitricoxidesynthase Y1 - 2012 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-123627 VL - 3 ER - TY - JOUR A1 - Volkert, Julia A1 - Zierhut, Kathrin C. A1 - Schiele, Miriam A. A1 - Wenzel, Martina A1 - Kopf, Juliane A1 - Kittel-Schneider, Sarah A1 - Reif, Andreas T1 - Predominant polarity in bipolar disorder and validation of the polarity index in a German sample N2 - Background: A large number of patients with bipolar disorder (BD) can be characterized by predominant polarity (PP), which has important implications for relapse prevention. Recently, Popovic et al. (EUR NEUROPSYCHOPHARM 22(5): 339–346, 2012) proposed the Polarity Index (PI) as a helpful tool in the maintenance treatment of BD. As a numeric expression, it reflects the efficacy of drugs used in treatment of BD. In the present retrospective study, we aimed to validate this Index in a large and well characterized German bipolar sample. Methods: We investigated 336 bipolar patients (BP) according to their PP and calculated the PI for each patient in order to prove if maintenance treatment differs according to their PP. Furthermore, we analysed whether PP is associated with demographic and clinical characteristics of BP. Results: In our sample, 63.9% of patients fulfilled criteria of PP: 169 patients were classified as depressive predominant polarity (DPP), 46 patients as manic predominant polarity (MPP). The two groups differed significantly in their drug regime: Patients with DPP were more often medicated with lamotrigine and antidepressants, patients with MPP were more often treated with lithium, valproate, carbamazepine and first generation antipsychotics. However, patients with DPP and MPP did not differ significantly with respect to the PI, although they received evidence-based and guideline-driven treatment. Conclusion: The reason for this negative finding might well be that for several drugs, which were used frequently, no PI value is available. Nevertheless we suggest PP as an important concept in the planning of BD maintenance treatment. KW - Bipolar disorder KW - Predominant polarity KW - Polarity index KW - Maintenance treatment KW - Depression KW - Mania KW - EBM Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-111042 ER - TY - JOUR A1 - Üçeyler, Nurcan A1 - Kewenig, Susanne A1 - Kafke, Waldemar A1 - Kittel-Schneider, Sarah A1 - Sommer, Claudia T1 - Skin cytokine expression in patients with fibromyalgia syndrome is not different from controls N2 - Background Fibromyalgia syndrome (FMS) is a chronic pain syndrome of unknown etiology. There is increasing evidence for small nerve fiber impairment in a subgroup of patients with FMS. We investigated whether skin cytokine and delta opioid receptor (DOR) gene expression in FMS patients differs from controls as one potential contributor to small nerve fiber sensitization. Methods We investigated skin punch biopsies of 25 FMS patients, ten patients with monopolar depression but no pain, and 35 healthy controls. Biopsies were obtained from the lateral upper thigh and lower calf. Gene expression of the pro-inflammatory cytokines tumor necrosis factor-alpha (TNF), interleukin (IL)-6, and IL-8 and of the anti-inflammatory cytokine IL-10 was analyzed using quantitative real-time PCR and normalizing data to 18sRNA as housekeeping gene. Additionally, we assessed DOR gene expression. Results All cytokines and DOR were detectable in skin samples of FMS patients, patients with depression, and healthy controls without intergroup difference. Also, gene expression was not different in skin of the upper and lower leg within and between the groups and in FMS patient subgroups. Conclusions Skin cytokine and DOR gene expression does not differ between patients with FMS and controls. Our results do not support a role of the investigated cytokines in sensitization of peripheral nerve fibers as a potential mechanism of small fiber pathology in FMS. KW - Fibromyalgia syndrome KW - Skin biopsy KW - Monopolar depression KW - Cytokines KW - Opioid receptor Y1 - 2014 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-110624 ER - TY - JOUR A1 - Rivero, Olga A1 - Reif, Andreas A1 - Sanjuan, Julio A1 - Molto, Maria D. A1 - Kittel-Schneider, Sarah A1 - Najera, Carmen A1 - Toepner, Theresia A1 - Lesch, Klaus-Peter T1 - Impact of the AHI1 Gene on the Vulnerability to Schizophrenia: A Case-Control Association Study N2 - Background: The Abelson helper integration-1 (AHI1) gene is required for both cerebellar and cortical development in humans. While the accelerated evolution of AHI1 in the human lineage indicates a role in cognitive (dys)function, a linkage scan in large pedigrees identified AHI1 as a positional candidate for schizophrenia. To further investigate the contribution of AHI1 to the susceptibility of schizophrenia, we evaluated the effect of AHI1 variation on the vulnerability to psychosis in two samples from Spain and Germany. Methodology/Principal Findings: 29 single-nucleotide polymorphisms (SNPs) located in a genomic region including the AHI1 gene were genotyped in two samples from Spain (280 patients with psychotic disorders; 348 controls) and Germany (247 patients with schizophrenic disorders; 360 controls). Allelic, genotypic and haplotype frequencies were compared between cases and controls in both samples separately, as well as in the combined sample. The effect of genotype on several psychopathological measures (BPRS, KGV, PANSS) assessed in a Spanish subsample was also evaluated. We found several significant associations in the Spanish sample. Particularly, rs7750586 and rs911507, both located upstream of the AHI1 coding region, were found to be associated with schizophrenia in the analysis of genotypic (p = 0.0033, and 0.031,respectively) and allelic frequencies (p = 0.001 in both cases). Moreover, several other risk and protective haplotypes were detected (0.006,p,0.036). Joint analysis also supported the association of rs7750586 and rs911507 with the risk for schizophrenia. The analysis of clinical measures also revealed an effect on symptom severity (minimum P value = 0.0037). Conclusions/Significance: Our data support, in agreement with previous reports, an effect of AHI1 variation on the susceptibility to schizophrenia in central and southern European populations. KW - Schizophrenie KW - Abelson helper integration-1 (AHI1) Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-68501 ER - TY - THES A1 - Kittel-Schneider, Sarah T1 - Expressionsanalytische und behaviourale Phänotypisierung der Nos1 Knockdown Maus T1 - Expressional and behavioural phenotyping of the Nos1 knockdown mouse N2 - Der gasförmige Neurotransmitter Stickstoffmonoxid (NO) spielt eine Rolle bei verschiedenen physiologischen Vorgängen, aber auch psychiatrischen Erkrankungen wie Aggression, Ängstlichkeit, Depression und auch bei kognitiven Funktionen. Um mehr über die physiologische Rolle von NO herauszufinden untersuchten wir mittels Gen-Expressionsanalyse und Verhaltensversuchen Mäuse, bei denen die neuronale Isoform der Stickstoffmonoxidsynthase ausgeschaltet wurde. Die so genannte NOS-I ist die hauptsächliche Quelle von NO im zentralen Nervensystem. Knockout Tiere sind wertvolle Werkzeuge um sowohl den Einfluss eines Gens auf Verhalten als auch möglicherweise damit zusammenhängende Veränderungen des Transkriptoms zu identifizieren. Dies ist wichtig um herauszufinden, mit welchen molekularen Pfaden bestimmte Verhaltensweisen korreliert sind. In Bezug auf NOS-I gibt es zwei bisher beschriebene Knockout Mäuse Stämme. Es existieren KOex6 Knockout Mäuse, in welchen es überhaupt keine katalytisch aktive NOS-I gibt und es gibt einen Mausstamm, bei dem Exon 1 deletiert wurde, was aufgrund alternativer NOS-I Splicevarianten zu einer residualen Expression von bis zu 7% führt. Daher sind diese Mäsue besser zutreffend als Knockdown Mäuse zu bezeichnen. In der vorliegenden Arbeit untersuchten wir die Nos1 Knockdown Mäuse, da die hier vorliegende Situation wohl ähnlicher zu der bei menschlicher genetischer Varianten ist, da eine komplette Disruption bisher noch nicht beim Menschen beschrieben wurde. Es gibt diverse Studien, welche den behaviouralen Phänotyp der Nos1 Knockdown Mäuse untersuchen, aber diese widersprechen sich zum Teil. Bei unserer Untersuchung legten wir den Schwerpunkt auf Verhaltenstests, welche spezifische Symptome des Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom (ADHS) aufdecken sollten. Wir führten den Elevated Plus Maze Test (EPM) und ein modifiziertes Lochbrett-Paradigma, die COGITAT-Box, durch. Um die den gefundenen Verhaltensänderungen zugrunde liegenden molekularen Mechanismen herauszufinden, suchten wir nach Unterschieden der Expression des Serotonin- (5HTT) und des Dopamintransporters (DAT) zwischen den Knockdown und den Wildtyp Mäusen. Wir hatten spekuliert, dass die Disruption der NOS-I zu einer modifizierten Expression des DAT oder des 5HTT geführt habe könnte wegen den bekannten engen Interaktionen zwischen dem nitrinergen und den monoaminergen Systemen. Wir fanden einen diskret anxiolytischen Phänotyp, da die Knockdown Mäuse eine längere Zeit auf dem offenen Arm des EPM verbrachten bzw. häufiger den offenen Arm betraten im Vergleich zu dem Wildtypen. Dies war nicht durch eine höhere lokomotorische Aktivität zu erklären. Auch beobachteten wir ein geschlechterunabhängiges kognitives Defizit im Arbeits- und Referenzgedächtnis in der COGITAT-Box. Überraschenderweise fanden wir keine signifikante Dysregulation der Monoamin-Transporter in der Expressionsanalyse mittels der quantitativen Real Time PCR. Dies war eher unerwartet, da vorherige Studien verschiedene Veränderungen im serotonergen und dopaminergen System bei den Nos1 Knockdown Mäusen gefunden hatten, wie z.B. einen verminderten Serotonin-Umsatz in frontalen Cortex und hypofunktionale 5 HT1A and 5HT1B Rezeptoren. Auch ist bekannt, dass NO direkt Monoamin-Transporter nitrosyliert. Zusammenfassend zeigen die Nos1 Knockdown Mäuse ein charakteristisches behaviourales Profil mit reduzierter Ängstlichkeit und Defiziten im Gedächtnis. Weitere Studien sollten folgen um zu klären, ob diese Mäuse als Tiermodell für z.B. die Alzheimer-Erkrankung oder das Aufmerksamkeitsdefizit-/Hyperaktivitätssyndrom dienen könnten und die weitere pathophysiologische Rolle des NO bei neuropsychiatrischen Erkrankungen herauszufinden. N2 - The gaseous messenger nitric oxide (NO) has been implicated in a wide range of behaviours, including aggression, anxiety, depression and cognitive functioning. To further elucidate the physiological role of NO and its down-stream mechanisms, we conducted behavioral and expressional phenotyping of mice lacking the neuronal isoform of nitric oxide synthase (NOS1), the major source of NO in the central nervous system. Knockout animals are valuable tools to identify both the behavioural impact of a given gene, as well as subsequent changes of the transcriptome to correlate behaviour to molecular pathways. With respect to NOS-I, two genetically modified mouse strains have been described in the literature. There are the KOex6 knockout mice in which you find a complete absence of catalytically active NOS-I and previously generated animals with a targeted deletion of exon 1 which show a residual NOS-I expression up to 7% rendering those mice actually Nos1 knockdown animals. In this study we used the knockdown animals because this situation seems to be more closely to human genetic variation, since a complete disruption of the gene has not yet been described in man. There a several studies on the behavioural phenotype of these animals but they are in part contradictory. In our investigations we had a special emphasis on ADHD-relevant tests, we performed the Elevated Plus Maze and a modified holeboard paradigm, the COGITAT Box. To further examine the underlying molecular mechanisms, we searched for differences in the expression of the serotonine and the dopamine transporter between the knockdown and the wildtype mice because we had speculated that disruption of the NOS-I might lead to a modified expression of the DAT or the 5HTT because of the tight interactions of NO and both the serotonergic as well as the dopaminergic system. A subtle anxiolytic phenotype was observed, with knockdown mice displaying a higher open arm time in the Elevated Plus Maze (student's t-test p>0.05) as compared to their respective wildtypes which was not caused by a higher locomotor acivity. Also there was gender-independent cognitive impairment in spatial learning and memory, as assessed by an automatized holeboard paradigm, the COGITAT Box. Here the working memory error and the reference memory error were in parts significantly different between knockdown animals and their respective wildtypes. Surprisingly no significant dysregulation of monoamine transporters was evidenced by qRT PCR. This we did not expect because of previous findings in Nos1 knockout mice that showed for example a reduced 5 HT turnover in the frontal cortex along with a concomitant increase in frontal 5-HT as well as 5 HT1A and 5HT1B receptor hypofunctioning and the fact that NO directly nitrosylates monoamine transporters. Taken together, Nos1 knockdown mice display a characteristic behavioural profile consisting of reduced anxiety and impaired learning and memory. Further research has to assess the value of these mice as animal models e.g. for Alzheimer’s disease or attention deficit disorder, in order to clarify a possible pathophysiological role of NO therein. KW - Aufmerksamkeits-Defizit-Syndrom KW - Stickstoffoxidsynthase KW - Dopaminstoffwechsel KW - Serotonin KW - Stickstoffmonoxid KW - Stickstoffmonoxid-Synthase KW - Arbeitsg KW - Dopamintransporter KW - Serotonintransporter KW - COGITAT-Box KW - Elevated Plus Maze KW - Nitric oxide synthase KW - Serotonine transporter KW - Dopamine Transporter KW - ADHD KW - Nitric oxide Y1 - 2010 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-52689 ER -